A total of 378 novel drugs and 27 biosimilars approved by the US Food and Drug
Administration (FDA) between 2010 and 2019 were evaluated according to approval …

Carbapenems are considered as last-resort antibiotics for the treatment of infections caused
by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in …

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have
encountered a worldwide success, particularly in K. pneumoniae isolates. These beta …

Abstract Multidrug-resistant (MDR) Gram-negative bacteria (GNB) pose a critical threat to
global healthcare, worsening outcomes and increasing mortality among infected patients …

Introduction Antimicrobial resistance (AMR) is an emerging global threat. It increases
mortality and morbidity and strains healthcare systems. Health care professionals can …

The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of β-lactamase inhibitor in
clinical development. We report that VNRX-5133 inhibits serine-β-lactamases (SBLs) and …

Infections caused by resistant bacteria are nowadays too common, and some pathogens
have even become resistant to multiple types of antibiotics, in which case few or even no …

The appearance of antibiotic drugs revolutionized the possibilities for treatment of diseases
with high mortality such as pneumonia, sepsis, plaque, diphtheria, tetanus, typhoid fever …

Introduction infections due to carbapenem-resistant Enterobacterales (CRE) constitute a
worldwide threat and are associated with significant mortality, especially in fragile patients …

The β-lactams remain the most important antibacterials, but their use is increasingly
compromised by resistance, importantly by β-lactamases. Although β-lactam and non-β …